Relapsed/Refractory B-ALL and NHL: Understanding CNCT19 CAR-T Pathways in Beijing

For relapsed or refractory B-ALL and NHL, waiting is not neutral. Disease burden, prior treatment, and timing can all change whether a CAR-T pathway is still realistic. This guide explains why Beijing gets attention, what records matter first, and where cost considerations may become relevant for international patients.